tbuckley/cabot-search huggingface dataset:
Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection
Authors: Ahmed Tawakol, Amorina Ishai, Danny Li, Richard A. P. Takx, Sophia Hur, Yannick Kaiser, Miguel Pampaloni, Adam Rupert, Denise Hsu, Irini Sereti, Rémi Fromentin, Nicolas Chomont, Peter Ganz, Steven G. Deeks, Priscilla Y. Hsue
Journal: JAMA Cardiology (2016)

Human immunodeficiency virus (HIV) infection is associated with a high risk of cardiovascular disease and increased arterial inflammation. In HIV, inflammation is also increased within lymph nodes (LNs), tissues known to harbor the virus even among treated and suppressed individuals.
Severe paediatric conditions linked with EV-A71 and EV-D68, France, May to October 2016
Authors: Denise Antona, Manoëlle Guillemin Kossorotoff, Isabelle Schuffenecker, Audrey Mirand, Marianne Leruez-Ville, Clément Bassi, Mélodie Aubart, Florence Moulin, Daniel Lévy-Bruhl, Cécile Henquell, Bruno Lina, Isabelle Desguerre
Journal: Eurosurveillance (2016)

We report 59 cases of severe paediatric conditions linked with enterovirus (EV)-A71 and EV-D68 in France between May and October 2016. Fifty-two children had severe neurological symptoms. EV sequence-based typing for 42 cases revealed EV-A71 in 21 (18 subgenotype C1, detected for the first time in France) and EV-D68 in eight. Clinicians should be encouraged to obtain stool and respiratory specimens from patients presenting with severe neurological disorders for EV detection and characterisation.
Myb Family Transcription Factors Contribute to G2/M Cell Cycle Transition in Normal and Malignant Hematopoietic Cells by Direct Regulation of Cyclin B1 Expression.
Authors: Yuji Nakata, Susan Shetzline, Chizuko Sakashita, Anna Kalota, Stephen I. Rudnick, Alan M. Gewirtz
Journal: Blood (2006)
Treatment of cholangiocarcinoma: Retrospective analysis of a single-center experience.
Authors: Ina Gaudig, Harald Schwoerer, Giuliano Ramadori
Journal: Journal of Clinical Oncology (2012)

376 Background: Cholangiocarcinomas (CC) are relatively rare neoplasms, but they show a rising incidence worldwide. CC orginate from epithelial cells lining the intra- and extrahepatic biliary tract including the gallbladder. Methods: We retrospectively evaluated 105 patients with CC treated in our centre between 2000 and 2010. This collective consisted of 45 women (42,9 %) and 60 men (57,1 %). The median age was 64 years (33 – 87 years). 23 % of the patients were adipose, 22 % were diabetic and 23 % suffered from neoplasms different from CC. Symptoms of patients at initial diagnosis of CC were: 47 % weight loss, 39 % upper abdominal pain, 36 % jaundice. Imaging diagnostics consisted of ultrasonography, endosonography, computertomography and eRCP. Tumormarkers as CA19-9 and CEA were elevated in 76 % and 48 % of patients with CC, respectively. Localization of CC: 46 % hilus (Klatskintumor), 23 % distal choledochal truct, 20 % intrahepatic, 11 % gallbladder. Results: For 57 patients (54,3 %) primary curative surgery of the CC was considered. 13/57 showed at laparoscopy inoperability. 3/48 patients treated with palliative chemotherapy showed regression of CC, allowing surgery. Thus, 47/105 (45 %) underwent curative surgery of CC. Surgical results: 39/47 (83 %) R0-resection, 7/47 (15 %) R1-resection, 1/47 Rx-resection. Median recidive – free survival for patients with R0-resection was 14,4 months, for R1-resection 1,8 months. The mean survival time of CC patients undergone curative surgery was 22 months, that of patients with palliative chemotherapy 5 months. 1 – 3 and 5 year survival for curatively resected CC patients were 78 %, 39 % and 21 %, respectively. Palliative chemotherapeutic treatment caused 26 %, 2,5 % and 0 %, respectively. In the whole collective, median survival under chemotherapy (mainly gemcitabine) was 9 months, with best supportive care 2,5 months. Conclusions: Resection of CC is treatment of choice in localized neoplasms. In advanced CC chemotherapy mainly based on gemcitabine was superior to best supportive care.
Impact of androgen deprivation therapy (ADT) on bone mineral density (BMD) over 3 years in men with nonmetastatic prostate cancer.
Authors: Shabbir M.H. Alibhai, Hassanabbas Z. Mohamedali, Abbas H. Panju, Narhari Timilshina, Henriette Breunis, Sarah Duff Canning, Neil Eric Fleshner, Murray Krahn, Gary Naglie, Ian Tannock, George A. Tomlinson, Padraig Richard Warde, Angela M Cheung
Journal: Journal of Clinical Oncology (2012)

193 Background: Decreased BMD is a common side effect of ADT, leading to increased fracture risk. Although loss of BMD appears to be greatest within the first 12 months of starting ADT, few data on BMD changes exist beyond 12 months, and other risk factors for bone loss in men on ADT are not well-characterized. Methods: Men age 50+ with non-metastatic prostate cancer and starting continuous ADT were enrolled in a prospective longitudinal study. BMD was determined by dual-energy x-ray absorptiometry at baseline and yearly for 3 years. A matched control group of men with prostate cancer but not on ADT was also enrolled. Medication use was recorded at each visit. Multivariable regression analyses were done to examine predictors of BMD loss. Results: 80 ADT users and 80 controls were enrolled (mean age 69.4 y); 49.7% had osteopenia and 4.6% had osteoporosis at baseline. ADT was associated with significant losses in lumbar spine BMD in year 1 compared to controls (p=0.004) and trends towards greater declines at femoral neck and total hip sites. Changes in year 2 and 3 were much smaller and not statistically different from controls (Table). Vitamin D use but not calcium use was associated with improved BMD at the lumbar spine in year 1 (+5.77%, p=0.006) with positive trends at other sites (+2.19% femoral neck, +1.76% total hip) primarily in year 1. Age was not associated with changes in BMD. Conclusions: Losses in BMD with ADT use are greatest at the lumbar spine and in the first year compared to years 2 and 3 and are independent of age. Vitamin D appears to be protective particularly in the first year of ADT use. [Table: see text]
A novel clinical score (<scp>InterTAK</scp> Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry
Authors: Jelena R. Ghadri, Victoria L. Cammann, Stjepan Jurisic, Burkhardt Seifert, L. Christian Napp, Johanna Diekmann, Dana Roxana Bataiosu, Fabrizio D'Ascenzo, Katharina J. Ding, Annahita Sarcon, Elycia Kazemian, Tanja Birri, Frank Ruschitzka, Thomas F. Lüscher, Christian Templin
Journal: European Journal of Heart Failure (2016)
Plasma Homocysteine Levels, Methelene TetraHydroFolate Reductase (MTHFR) Polymorphism, and the Risk of Thromboembolism in Children: A Single Institution Experience
Authors: Akash Nahar, Yaddanapudi Ravindranath, Jeanne M. Lusher, Meera B. Chitlur, Mary Jane Frey, Cynthia Sabo, Madhvi Rajpurkar
Journal: Blood (2008)
Lenalidomide Induced Cytokine Release Syndrome in Chronic Lymphocytic Leukemia (CLL): Clinical and Laboratory Correlates of Immune Activation.
Authors: Georg Aue, Ndegwa Njuguna, Xin Tian, Janet Valdez, Susan Soto, J. Philip McCoy, Leigh Samsel, Berengere Vire, Keyvan Keyvanfar, Stefania Pittaluga, Adrian Wiestner
Journal: Blood (2008)
The importance of the patient voice in vaccination and vaccine safety—are we listening?
Authors: D. Holt, F. Bouder, C. Elemuwa, G. Gaedicke, A. Khamesipour, B. Kisler, S. Kochhar, R. Kutalek, W. Maurer, P. Obermeier, L. Seeber, B. Trusko, S. Gould, B. Rath
Journal: Clinical Microbiology and Infection (2016)
Use of CDK1 and CDK2 activity to predict renal cell cancer recurrence.
Authors: F. Hongo, N. Takaha, Y. Kimura, T. Nakamura, K. Mikami, S. Nakayama, T. Matsushima, H. Ishihara, T. Sakai, T. Miki
Journal: Journal of Clinical Oncology (2011)

341 Background: We established original methods enabling simultaneous analysis of protein expressions and kinase activities of the CDK (cyclin-dependent kinase) molecules in lysate of tumor tissue in a clinical setting (C2P technology, Ishihara et al: Biochim Biophys Acta. 1741; 226-233, 2005). The clinical utility of the technology was first evaluated in breast cancer, and combination analysis of CDK1 and CDK2 activity was shown to be a significant prognostic indicator for relapse (Kim et al. Ann Oncol. 19;68-72,2009). The objective of our study is to evaluate the efficacy of CDK1 and CDK2 activity as a prognostic marker in human renal cell carcinoma (RCC). Methods: Surgical specimens were obtained from 115 patients with RCC without metastasis. These patients were selected randomly for this study. Protein expression and kinase activity of CDKs and cyclins were analyzed using a newly developed assay system. The system to measure the CDK specific activity (SA) is named C2Ps (Sysmex, Kobe, Japan). We then examined the specific activities of CDK1 and CDK2 and calculated CDK2/CDK1 ratio in RCC. Also, risk score (RS) was examined as described in previous study (JGH van Nes et al: Br J Cancer. 100; 494-500, 2009). Cut off value was calculated by ROC analysis. Results: 115 cases were tested, though 32 cases were excluded of low sample quality (30 cases) and of assay failure (2 cases). 83 cases were analyzed. They included 63 male and 20 female patients, ranging in age from 19 to 83 years. At a median follow up of 33 months (1-109M), tumor with low CDK2/CDK1 ratio showed significantly better 5-year progression-free survival (PFS) than those with high CDK2/CDK1 ratio (91.2% vs. 51.6%, p=0.0016). Also, RS enabled the classification of RCCs into high-risk and low-risk groups, patients with tumors classified as low RS showed better PFS than patients with tumors with high RS (88.9% vs. 63.9%, p=0.0488). Conclusions: CDK1 specific activity of tumors and the CDK2 specific activity are both associated with recurrence and prognosis. Analysis of cyclin-dependent kinase activity in the clinical setting could be a powerful approach for predicting cancer recurrence and prognosis in RCC after surgery and has potential for use as a routine laboratory test. No significant financial relationships to disclose.
2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
Authors: Frederick L Grover, Sreekanth Vemulapalli, John D Carroll, Fred H Edwards, Michael J Mack, Vinod H Thourani, Ralph G Brindis, David M Shahian, Carlos E Ruiz, Jeffrey P Jacobs, George Hanzel, Joseph E Bavaria, E Murat Tuzcu, Eric D Peterson, Susan Fitzgerald, Matina Kourtis, Joan Michaels, Barbara Christensen, William F Seward, Kathleen Hewitt, David R Holmes
Journal: Journal of the American College of Cardiology (2016)
Correlation of percent of core biopsies positive for prostate cancer and biochemical outcome following I-125 prostate brachytherapy or external beam radiation.
Authors: R. D. Tendulkar, K. L. Stephans, C. A. Reddy, K. Martires, A. R. Patel, D. Raj, D. Lowes, T. Geng, E. A. Klein, J. P. Ciezki
Journal: Journal of Clinical Oncology (2011)

40 Background: The percentage of positive cores (PPC) on biopsy for prostate cancer has been identified as a predictor of outcome following definitive local treatment. We aim to identify whether this observation holds true for a modern cohort of patients (pts) treated at Cleveland Clinic with permanent prostate brachytherapy (PB) or external beam radiation therapy (EBRT). Methods: We retrospectively reviewed pathology reports of pts treated with either PB or EBRT from our IRB-approved prospective prostate cancer registry. No pts underwent both PB and EBRT. The number of biopsy cores sampled, number of cores positive for prostate cancer, and maximum length of any core positive for prostate cancer were collected. Cox proportional hazards regression was used to analyze biochemical relapse free survival (bRFS) using the nadir + 2 ng/ml definition. Results: We identified 1253 PB and 879 EBRT pts with complete pathology and clinical information. Among PB pts, 46% were low risk, 40% intermediate risk, and 14% high risk, while 78% had &lt;50% PPC, and 22% had &gt;=50% PPC. The 5-year bRFS for PB was 92.0% for &lt;50% PPC, vs. 83.1% for &gt;=50% PPC (HR 2.1, p=0.0005). For PB pts, significant predictors of bRFS on univariate analysis included: PPC, clinical T stage, PSA, biopsy Gleason score, androgen deprivation, and frequency of PSA testing. On multivariate analysis, only PPC, biopsy Gleason score, and PSA frequency remained significant predictors following PB. Among EBRT pts, 11% were low risk, 36% intermediate risk, and 53% high risk, while 55% had &lt;50% PPC, and 45% had &gt;=50% PPC. The 5-year bRFS for EBRT was 85.6% for &lt;50% PPC, vs. 77.1% for &gt;=50% PPC (HR 1.8, p&lt;0.0001). For EBRT pts, significant predictors of bRFS on univariate analysis included: PPC, clinical T stage, PSA, biopsy Gleason score, androgen deprivation, EBRT dose, and frequency of PSA testing. On multivariate analysis, only PPC, biopsy Gleason score, and PSA frequency remained significant predictors following EBRT. Conclusions: Following PB or EBRT, the percent of positive cores for prostate cancer was a significant predictor of bRFS on multivariate analysis, more so than conventional predictors such as T stage and PSA. No significant financial relationships to disclose.
Efficacy of triptorelin in lowering serum testosterone (sT) in patients with advanced prostate cancer.
Authors: N. Mounedji, E. A. Lundstroem, D. Purcea, P. Grosgurin, H. C. Porchet
Journal: Journal of Clinical Oncology (2011)

162 Background: Medical castration using gonadotropin-releasing hormone (GnRH) agonists is the mainstay of treatment for advanced prostate cancer. Achievement and maintenance of castrate serum testosterone (sT) levels &lt;50 ng/dL (1.735 nmol/mL) has been the goal of therapy. However, patients are able to achieve and maintain sT levels &lt;15 ng/dL after surgical castration (Oefelein M et al. J Urology 2000; 56: 1021-4). Some authors have suggested that 20 ng/dL should be the target threshold for medical castration(Perachino M et al. BJU Int 2010; 105: 648-51) but the clinical relevance of achieving such low sT levels (&lt;20 ng/dL) remains unknown. Methods: The efficacy and safety of sustained-release triptorelin pamoate 22.5 mg 6-month formulation was recently evaluated in a 12-month (48-week), multicentre, open-label, phase III study in 120 patients with locally advanced or metastatic prostate cancer and/or increased prostate specific antigen (PSA) after failed local therapy. Initial results based on the standard castration level of 50 ng/dL were previously presented in comparison to triptorelin 1- and 3-month formulations (Lundström E et al. Clin Drug Investig 2009; 29: 757-65). We report the proportions of patients achieving sT levels of &lt;20 ng/dL with the triptorelin pamoate 1-, 3- and 6-month formulations. Results: With the 6-month formulation, sT levels of &lt;20 ng/dL were achieved in &gt;90% of patients on Day 169 (6 months after first triptorelin injection) and on Day 337 (6 months after second injection; Table). Similar sT levels were achieved with triptorelin 1- and 3-month formulations in a phase III study over 9 months (Table). Conclusions: A high proportion of patients receiving the 6-month triptorelin formulation achieve sT levels &lt;20 ng/dL. This compares favorably to the triptorelin 1- and 3-month formulations. [Table: see text] [Table: see text]
Acupuncture for Chronic Severe Functional Constipation
Authors: Zhishun Liu, Shiyan Yan, Jiani Wu, Liyun He, Ning Li, Guirong Dong, Jianqiao Fang, Wenbin Fu, Lixin Fu, Jianhua Sun, Linpeng Wang, Shun Wang, Jun Yang, Hongxing Zhang, Jianbin Zhang, Jiping Zhao, Wei Zhou, Zhongyu Zhou, Yanke Ai, Kehua Zhou, Jia Liu, Huanfang Xu, Yuying Cai, Baoyan Liu
Journal: Annals of Internal Medicine (2016)

Acupuncture has been used for chronic constipation, but evidence for its effectiveness remains scarce.To determine the efficacy of electroacupuncture (EA) for chronic severe functional constipation (CSFC).Randomized, parallel, sham-controlled trial. (ClinicalTrials.gov: NCT01726504).15 hospitals in China.Patients with CSFC and no serious underlying pathologic cause for constipation.28 sessions of EA at traditional acupoints or sham EA (SA) at nonacupoints over 8 weeks.The primary outcome was the change from baseline in mean weekly complete spontaneous bowel movements (CSBMs) during weeks 1 to 8. Participants were followed until week 20.1075 patients (536 and 539 in the EA and SA groups, respectively) were enrolled. The increase from baseline in mean weekly CSBMs during weeks 1 to 8 was 1.76 (95% CI, 1.61 to 1.89) in the EA group and 0.87 (CI, 0.73 to 0.97) in the SA group (between-group difference, 0.90 [CI, 0.74 to 1.10]; P < 0.001). The change from baseline in mean weekly CSBMs during weeks 9 to 20 was 1.96 (CI, 1.78 to 2.11) in the EA group and 0.89 (CI, 0.69 to 0.95) in the SA group (between-group difference, 1.09 [CI, 0.94 to 1.31]; P < 0.001). The proportion of patients having 3 or more mean weekly CSBMs in the EA group was 31.3% and 37.7% over the treatment and follow-up periods, respectively, compared with 12.1% and 14.1% in the SA group (P < 0.001). Acupuncture-related adverse events during treatment were infrequent in both groups, and all were mild or transient.Longer-term follow-up was not assessed. Acupuncturists could not be blinded.Eight weeks of EA increases CSBMs and is safe for the treatment of CSFC. Additional study is warranted to evaluate a longer-term treatment and follow-up.Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program.
Effectiveness of foot orthoses and shock-absorbing insoles for the prevention of injury: a systematic review and meta-analysis
Authors: Daniel R Bonanno, Karl B Landorf, Shannon E Munteanu, George S Murley, Hylton B Menz
Journal: British Journal of Sports Medicine (2016)

Objective To investigate the evidence relating to the effectiveness of foot orthoses and shock-absorbing insoles for the prevention of musculoskeletal injury. Design Systematic review and meta-analysis. Eligibility criteria for selecting studies Clinical trials evaluating the effectiveness of foot orthoses and shock-absorbing insoles for the prevention of injury. Data sources Cochrane Library, CINAHL, EMBASE, MEDLINE and SPORTDiscus from their inception up to the first week of June 2016. Results 11 trials that had evaluated foot orthoses and 7 trials that had evaluated shock-absorbing insoles were included. The median Physiotherapy Evidence Database (PEDro) score for trials that had evaluated foot orthoses and shock-absorbing insoles was 5 (range 3–8/10) and 3 (range 1–7/10), respectively. Meta-analysis found that foot orthoses were effective for preventing overall injuries (risk ratio (RR) 0.72, 95% CI 0.55 to 0.94) and stress fractures (RR 0.59, 95% CI 0.45 to 0.76), but not soft-tissue injuries (RR 0.79, 95% CI 0.55 to 1.14). In contrast, shock-absorbing insoles were not effective for preventing overall injuries (RR 0.92, 95% CI 0.73 to 1.16), stress fractures (RR 1.15, 95% CI 0.57 to 2.32) or soft-tissue injuries (RR 0.92, 95% CI 0.74 to 1.15). Conclusions Foot orthoses were found to be effective for preventing overall injuries and stress fractures but not soft-tissue injuries, while shock-absorbing insoles were not found to be effective for preventing any injury. However, further well-designed trials will assist the accuracy and precision of the estimates of risk reduction as the quality of the included trials varied greatly.
Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.
Authors: Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Lisa Kujawski, Ehab Atallah, Peter Marks, Donna Di Gravio, Lisa Pyle, Syed Rizvi, Jean-Pierre J Issa
Journal: Blood (2009)
Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC).
Authors: Amado J. Zurita, Mehrdad Khajavi, Xuemei Wang, Christopher G. Wood, Surena F. Matin, Stefania Fiorentino, Kathryn S. McKee, Hai T. Tran, John Heymach, Eric Jonasch
Journal: Journal of Clinical Oncology (2012)

383 Background: Although recent years have brought great progress into understanding the pathogenesis of RCC and multiple promising biomarkers, no tumor tissue or blood-based test has yet been validated for clinical use. The main objectives of this exploratory analysis were to identify CAFs predictive of recurrence in RCC pts, and to gain insight into tumor dependency of individual factors by comparing CAFs pre- and post-nephrectomy (Nx). Methods: Plasma samples were obtained before and up to 1 year after Nx from pts with sporadic, non-metastatic renal masses suspicious for RCC (n=73). Upon Nx, 52 pts showed dominant clear cell histology and 11 non-clear cell; 10 pts had non-cancerous lesions. RCC pts were categorized by risk of relapse based on pathologic staging (pT1/pT2 as low-risk [LR], n=38; pT3/pT4 as high-risk [HR], n=25). Multiplex bead suspension arrays and ELISA were used to measure concentrations of 58 CAFs including angiogenesis and invasion mediators (VEGF, VEGF-C, soluble CAIX [sCA9], hepatocyte growth factor and transforming growth factor-b1, among others), and multiple inflammatory and/or immunomodulatory chemokines and interleukins (IL). t-test and Wilcoxon signed rank or rank-sum tests were respectively used to assess changes in CAFs between pre- and post-Nx or to compare CAFs between subgroups of pts. Results: Of 58 pre-Nx CAFs available in RCC pts, the concentrations of IL-8, granulocyte-colony stimulating factor, stromal cell-derived factor-1, and osteopontin, among others, were significantly higher in HR vs. LR-RCC (all P&lt;0.01). In pts with clear cell RCC, sCA9 was also higher (P=0.004). A number of CAFs significantly decreased post-Nx, including sCA9, endoglin, and e-selectin, while others increased, such as stem cell factor, IL-12, and vascular cell adhesion molecule-1. The pre-Nx concentrations of e-selectin were lower in pts with eventual disease recurrence (P=0.008). Conclusions: We identified pre-Nx CAFs associated with risk for recurrence, and post-Nx changes related to the presence of the tumor in pts with non-metastatic RCC. If validated in a larger study, these CAFs could be used for risk stratification of RCC pts.
The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study
Authors: Anas Younes, Francisco Hernandez, R. Gregory Bociek, Yvette L. Kasamon, Peter Lee, Lia Gore, Amanda R Copeland
Journal: Blood (2011)